CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Linagliptin

Linagliptin

Last Updated: August 23, 2011

Result type: Reports

Project Number: SR0244-000

Product Line: Reimbursement Review

Generic Name: Linagliptin

Brand Name: Trajenta

Manufacturer: Boehringer Ingelheim Canada

Therapeutic Area: Diabetes mellitus, type 2

Indications: Diabetes mellitus, Type 2

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 15, 2012

Recommendation Type: List with clinical criteria and/or conditions

Linagliptin

Files